Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, Veterans' Affairs, Oversight and Government Reform, and Natu…
The bill directs HHS to set annual reference prices for every prescription drug, using the lowest retail list price among a set of foreign reference countries when possible. Those reference prices cap the retail list price for beneficiaries in specified Federal health programs, and manufacturers must offer drugs to all purchasers at the reference price.
Progressives emphasize access and NIH funding benefits
Relative to its intended legislative type, this bill is a substantive policy change with a clear high-level framework: HHS must set annual reference prices using a specified set of reference countries or specified factors, those prices limit retail list prices for a broad set of Federal health program enrollees, manufacturers must offer the reference price to other purchasers, and noncompliance triggers a sizable civil penalty with penalty proceeds directed to NIH.
The bill directs HHS to set annual reference prices for every prescription drug, using the lowest retail list price among a set of foreign reference countries when possible.
Those reference prices cap the retail list price for beneficiaries in specified Federal health programs, and manufacturers must offer drugs to all purchasers at the reference price.
Noncompliant manufacturers face civil penalties equal to five times the excess revenue, with penalties transferred to NIH for drug R&D.
Sweeping federal price controls with major fiscal and regulatory consequences and clear powerful stakeholder pushback; unlikely without major narrowing or compromise.
Relative to its intended legislative type, this bill is a substantive policy change with a clear high-level framework: HHS must set annual reference prices using a specified set of reference countries or specified factors, those prices limit retail list prices for a broad set of Federal health program enrollees, manufacturers must offer the reference price to other purchasers, and noncompliance triggers a sizable civil penalty with penalty proceeds directed to NIH. The bill includes concrete elements (reference-country list, penalty formula, program scope, applicability to branded and generic/biologic approvals).
Progressives emphasize access and NIH funding benefits
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize access and NIH funding benefits
Likely supportive; sees the bill as a strong federal tool to curb excessive drug prices and expand access.
Views penalty-to-NIH funding as a public-good reinvestment into R&D.
May want additional safeguards for low-income patients and coverage gaps.
Cautiously receptive: appreciates aims to reduce costs, but worries about implementation, legal exposure, and unintended supply or innovation effects.
Would favor phased rollout, clear appeals, and empirical monitoring.
Wants balanced cost controls without destabilizing drug markets.
Likely opposed: views the bill as federal price control and government overreach that threatens innovation and market incentives.
Sees extraterritorial benchmarking to foreign prices as inappropriate.
Concerned about punitive enforcement and negative economic effects.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Sweeping federal price controls with major fiscal and regulatory consequences and clear powerful stakeholder pushback; unlikely without major narrowing or compromise.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize access and NIH funding benefits
Sweeping federal price controls with major fiscal and regulatory consequences and clear powerful stakeholder pushback; unlikely without maj…
Relative to its intended legislative type, this bill is a substantive policy change with a clear high-level framework: HHS must set annual reference prices using a specified set of reference countries or specified facto…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.